Biologics Safety: Infection Risk, Screening, and Vaccination Guidance

Starting a biologic for an autoimmune condition can feel like a lifeline, but it also opens the door to a higher risk of infections. If you or a loved one is about to start medication like Humira (adalimumab) or Stelara (ustekinumab), understanding the safety protocol isn't just bureaucratic red tape-it's your primary defense against serious illness. The core issue is simple: these drugs work by calming down your immune system, which means your body is less equipped to fight off everyday germs. Without proper preparation, patients face a significantly elevated chance of hospitalization due to respiratory, urinary, or skin infections.

This guide breaks down exactly what that "preparation" looks like in 2026. We are moving beyond vague advice to look at specific blood tests, precise vaccination timelines, and the real-world data on how much risk different drug classes actually carry. By the end, you will have a clear checklist to discuss with your rheumatologist or gastroenterologist, ensuring you aren't just taking a prescription, but managing a complex medical strategy.

Understanding the Real Infection Risk

It is easy to dismiss infection risk as a worst-case scenario, but the numbers tell a different story. Data from large-scale claims databases shows that patients on biologics have a 2.1 times higher adjusted risk of hospitalized infections compared to those on non-biologic therapies. This isn't just a theoretical stat; it translates to thousands of preventable hospital visits every year. The risk isn't uniform across all drugs, though. Older agents like TNF inhibitors (Infliximab, Etanercept) have been around longer and have more extensive safety data, showing slightly higher baseline risks than some newer mechanisms.

Your personal risk profile depends heavily on three factors: age, concurrent medications, and existing health conditions. Being over 50 increases your risk by roughly 37% per decade. If you are also taking prednisone at doses higher than 10mg daily, that risk multiplies further. Conditions like diabetes, chronic kidney disease, and COPD act as force multipliers for infection susceptibility. For example, patients with COPD on biologics have an odds ratio of 2.41 for serious infections compared to healthy controls. Understanding where you fall on this spectrum helps determine how aggressive your screening needs to be.

The Mandatory Pre-Biologic Screening Checklist

Before the first dose hits your vein or skin, your doctor should run a specific set of blood tests. These aren't optional extras; they are standard of care guidelines established by the American College of Rheumatology (ACR) and the FDA. Missing these steps is the most common reason for post-treatment complications.

• Tuberculosis (TB) Testing: You need an interferon-gamma release assay (IGRA), such as QuantiFERON-TB Gold. Even if you've never lived in a high-prevalence area, latent TB can reactivate when your immune system is suppressed. A positive result usually means 9 months of antibiotic treatment before starting the biologic.
• Hepatitis B Virus (HBV): This is critical. You need testing for HBsAg, HBsAb, and HBcAb. Many people don't know they carry the virus because it lies dormant. Reactivation without prophylaxis happens in up to 27.6% of untreated cases, leading to liver failure. If your core antibody (HBcAb) is positive, you likely need an HBV DNA test regardless of other results.
• Hepatitis C Virus (HCV): Standard antibody testing is required. While less risky than Hep B reactivation, active HCV complicates immunosuppression therapy.
• Varicella-Zoster Virus (VZV): Also known as chickenpox/shingles. Your doctor checks IgG levels. If you are seronegative (no immunity), you must get vaccinated before starting the biologic, as live vaccines won't work once the drug is in your system.
• Complete Blood Count (CBC): To ensure your white blood cell count is stable enough to handle the medication.

A major pitfall here is incomplete testing. Surveys of patient experiences show that nearly 40% of screening omissions involve missing the Hepatitis B core antibody test. Always ask your provider specifically: "Did we check my HBcAb?" It’s a simple question that prevents a potentially life-threatening complication.

Vaccination Timing: The Critical Window

Vaccines are your best friend when starting biologics, but timing is everything. Because many biologics suppress the immune response, your body may not build adequate protection if you vaccinate *after* starting the drug. The general rule of thumb is to get all necessary shots done before the first dose.

For shingles specifically, the recombinant vaccine Shingrix is preferred over the older live Zostavax. Recent trials suggest that getting Shingrix before starting a TNF inhibitor reduces the risk of developing shingles during treatment. If you missed this window, don't panic-your doctor may still administer it, but they might monitor you more closely for breakthrough infections. Also, remember that annual flu shots remain crucial, even after starting the biologic, though your immune response to them may be slightly blunted.

Comparing Drug Classes: Which Are Safer?

Not all biologics carry the same infection burden. If you are a candidate for multiple types of medication, discussing the safety profile with your specialist can influence the decision. TNF inhibitors have been the gold standard for decades, but newer classes like IL-17 inhibitors and JAK inhibitors offer different risk-reward ratios.

IL-12/23 inhibitors, such as Stelara, generally show lower rates of serious infections compared to TNF inhibitors in head-to-head analyses. However, they carry a slightly higher risk of oral thrush (candidiasis). JAK inhibitors, which are small molecules rather than true biologics but often used in similar contexts, have a distinct profile: they increase the risk of herpes zoster (shingles) by about 1.33 times compared to biologic DMARDs. This makes prior shingles vaccination almost mandatory for anyone considering a JAK inhibitor.

If you have a history of heart failure or demyelinating disease, TNF inhibitors might be contraindicated entirely, pushing you toward other classes. But for pure infection risk, the difference between top-tier agents is often manageable through good hygiene and screening. The bigger determinant of your safety is whether you follow the pre-treatment protocol rigorously.

Navigating the First Year: Monitoring and Red Flags

Once the biologic is started, the job isn't done. The first six months are the highest-risk period for opportunistic infections. Your care team should schedule regular check-ups, typically every 3 months initially, to review any new symptoms. You become your own first line of defense by knowing the red flags that warrant an immediate call to your doctor.

• Fever: Any temperature above 100.4°F (38°C) that lasts more than 24 hours.
• Respiratory Symptoms: Persistent cough, shortness of breath, or chest pain, especially if you have a history of lung disease.
• Skin Changes: New rashes, sores that don't heal, or signs of fungal infection (white patches in mouth/throat).
• Urinary Issues: Burning during urination or frequent urges, which could indicate a UTI progressing to a kidney infection.

Don't ignore minor symptoms thinking they will pass. In an immunocompromised state, a simple cold can escalate quickly. Keep a log of any unusual symptoms and share it at your next appointment. Additionally, practice basic hygiene aggressively: wash hands frequently, avoid sick contacts when possible, and keep vaccinations up to date. The CDC’s 12-point infection prevention checklist is a useful tool to keep on your fridge; studies show patients who actively use these educational materials report significantly fewer serious infections.

Practical Tips for Patients and Caregivers

Managing biologics safety is a partnership between you, your specialist, and your primary care provider. Often, the specialist starts the drug, but the PCP manages the day-to-day health. Make sure both doctors are communicating. Send copies of your screening results to everyone involved in your care. If you travel, carry a card listing your medication, its mechanism (immunosuppressant), and any allergies. This helps emergency providers make faster, safer decisions.

If you are planning a pregnancy or undergoing surgery, notify your team well in advance. Some biologics cross the placenta, and surgical sites may require temporary pauses in therapy to reduce wound infection risk. Finally, stay informed but don't let anxiety paralyze you. The vast majority of patients on biologics thrive with their conditions controlled and remain healthy. The key is proactive management, not reactive worry. By treating the safety protocol as seriously as the medication itself, you maximize the benefits of modern autoimmune therapy while keeping your risks low.